Related Experiment Video

Updated: Dec 2, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.2K

Two-year outcomes after dextrose gel prophylaxis for neonatal hypoglycaemia

Rebecca Griffith1, Joanne Elizabeth Hegarty2, Jane M Alsweiler1,2

  • 1Department of Paediatrics: Child and Youth Health, The University of Auckland, Auckland, New Zealand.

Archives of Disease in Childhood. Fetal and Neonatal Edition
|November 5, 2020
PubMed

Insights

Prophylactic dextrose gel did not affect neurodevelopment or executive function in infants at 2 years corrected age. The study was underpowered to detect potential effects on neurosensory outcomes.

Area of Science:

  • Neonatal medicine
  • Developmental pediatrics
  • Clinical trials

Background:

  • Neonatal hypoglycemia is a common concern in newborns.
  • Early interventions are crucial for optimal infant neurodevelopment.
  • Dextrose gel is used to prevent and treat neonatal hypoglycemia.

Purpose of the Study:

  • To evaluate the long-term neurodevelopmental and executive function outcomes at 2 years corrected age in infants who received prophylactic dextrose gel.
  • To assess the safety and efficacy of different dextrose gel dosages.

Main Methods:

  • Prospective follow-up of a randomized controlled trial (pre-hPOD trial).
  • Participants received buccal 40% dextrose gel or placebo in four different dose regimens.
  • Neurodevelopment and executive function were assessed at 2 years corrected age.

Main Results:

  • No significant differences were found in neurosensory impairment or executive function between dextrose gel and placebo groups.
  • No differences were observed in secondary outcomes, including neurology and anthropometry.
  • Infants who did or did not develop neonatal hypoglycemia showed no difference in neurodevelopmental outcomes.

Conclusions:

  • Prophylactic dextrose gel did not alter neurodevelopment or executive function at 2 years corrected age.
  • The intervention showed no adverse effects up to 2 years corrected age.
  • The study was underpowered to detect clinically significant effects on neurosensory outcomes.
Abstract

Keywords:
neonatologyneurology

More Related Videos

Probiotic Studies in Neonatal Mice Using Gavage10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

20.4K
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

374

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
654
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.0K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.7K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
125
Outcomes of Glycolysis01:13

Outcomes of Glycolysis

Nearly all the energy used by cells comes from the bonds that make up complex organic compounds. These organic compounds are broken down into simpler molecules, such as glucose. As a result, cells extract energy from glucose over many chemical reactions—a process called cellular respiration.
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
105.9K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
498